SUTRO BIOPHARMA, INC.(STRO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,854 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in STRO
Events flagged as statistical outliers against STRO's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-14
STRO quality score dropped 14 points (25→11) on a new filing
View source filing →
STRO Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for SUTRO BIOPHARMA, INC. (STRO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STRO at 15.3/100 on a 32-signal composite quality model, placing it at rank #2,854 of 2,961 stocks — the bottom half of the AI-ranked universe. STRO scores in the top quartile across institutional flow (92.7). Areas of concern include balance sheet strength (1.6) and free cash flow (3.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), SUTRO BIOPHARMA, INC. reports quarterly revenue of $9.8M, net income of $-38.5M. Top institutional holders of STRO by reported 13-F value include PERCEPTIVE ADVISORS, BVF, Affinity Asset Advisors, based on the most recent SEC filings. STRO trades on the Nasdaq exchange and files with the SEC under CIK 1382101. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STRO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SUTRO BIOPHARMA, INC. directly from SEC EDGAR. SUTRO BIOPHARMA, INC.'s 13F Pro composite quality score has ranged between 8 and 30 since 2021, currently 15.3 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$9.8M
Net Income
Q2 2026
$-38.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+65.2% YoYNet Income
+16.0% YoYOperating Income
+33.6% YoYEPS (Diluted)
+23.5% YoYTotal Assets
-55.1% YoYTotal Debt
Op. Cash Flow
+7.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $102.5M +65.2% | $62.0M -59.6% | $153.7M +126.8% | $67.8M +9.5% | $61.9M +44.8% | $42.7M |
| Net Income | $-191.1M +16.0% | $-227.5M -113.0% | $-106.8M +10.4% | $-119.2M -12.9% | $-105.5M -228.5% | $-32.1M |
| Operating Income | $-158.4M +33.6% | $-238.5M -167.1% | $-89.3M +30.8% | $-128.9M -30.9% | $-98.5M -38.7% | $-71.1M |
| EPS (Diluted) | $-22.49 +23.5% | $-29.40 -1551.7% | $-1.78 +24.3% | $-2.35 -2.6% | $-2.29 -131.3% | $-0.99 |
| Total Assets | $173.8M -55.1% | $387.2M -17.7% | $470.7M +15.7% | $406.9M +19.2% | $341.4M -13.4% | $394.1M |
| Total Debt | — | — | $12.2M -70.5% | $41.3M -5.9% | $43.9M +78.7% | $24.5M |
| Operating Cash Flow | $-177.2M +7.5% | $-191.5M -71.6% | $-111.6M -3245.0% | $3.5M +104.3% | $-81.7M -20.5% | $-67.8M |
Get alerted when STRO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for SUTRO BIOPHARMA, INC. including:
Top Institutional Holders of STRO
PERCEPTIVE ADVISORS LLC
$43.3M1,304,846 shBVF INC/IL
$41.6M1,251,788 shAffinity Asset Advisors, LLC
$38.9M1,172,487 shBlackRock, Inc.
$37.3M1,122,655 shSamsara BioCapital, LLC
$35.3M1,062,872 shKynam Capital Management, LP
$29.0M872,558 shORBIMED ADVISORS LLC
$24.7M743,944 shBALYASNY ASSET MANAGEMENT L.P.
$23.6M711,162 shVANGUARD CAPITAL MANAGEMENT LLC
$23.0M694,219 shEVENTIDE ASSET MANAGEMENT, LLC
$19.4M585,262 sh
| Fund | Value | Shares |
|---|---|---|
| PERCEPTIVE ADVISORS LLC | $43.3M | 1,304,846 |
| BVF INC/IL | $41.6M | 1,251,788 |
| Affinity Asset Advisors, LLC | $38.9M | 1,172,487 |
| BlackRock, Inc. | $37.3M | 1,122,655 |
| Samsara BioCapital, LLC | $35.3M | 1,062,872 |
| Kynam Capital Management, LP | $29.0M | 872,558 |
| ORBIMED ADVISORS LLC | $24.7M | 743,944 |
| BALYASNY ASSET MANAGEMENT L.P. | $23.6M | 711,162 |
| VANGUARD CAPITAL MANAGEMENT LLC | $23.0M | 694,219 |
| EVENTIDE ASSET MANAGEMENT, LLC | $19.4M | 585,262 |
Companies Similar to STRO
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
CytomX Therapeutics, Inc.
Alector, Inc.
NEKTAR THERAPEUTICS
Prelude Therapeutics Inc
Celldex Therapeutics, Inc.
Avalo Therapeutics, Inc.
Entrada Therapeutics, Inc.
Nurix Therapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put STRO on your watchlist
Track score changes the day SUTRO BIOPHARMA, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is STRO a good stock to buy?
13F Pro's AI-powered analysis of SUTRO BIOPHARMA, INC. (STRO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for STRO are available on the STRO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. STRO is classified as a small company.
Which hedge funds own STRO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling STRO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SUTRO BIOPHARMA, INC.'s investment landscape.